Rituximab is probably no longer the treatment of choice for ITP secondary therapy for the majority of patients. Although it has a good initial response, the majority of patients relapse in the first 1 to 2 years leaving a choice of retreating and persistent immunosuppression or trying another therap...
Agree, rituximab or TPO agonist depending on the s...